New drug nemolizumab tested for rare skin disease
NCT ID NCT05214794
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tested the drug nemolizumab in 6 people with systemic sclerosis, a rare disease that causes skin thickening. The goal was to see if the drug could improve skin symptoms and to check its safety. Participants received injections of nemolizumab, and doctors measured skin thickness over 24 and 52 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nemolizumab
What this could lead to
If it works, this could point toward a treatment to reduce skin thickening in systemic sclerosis.
What could go wrong
This is a very small, early-phase trial with only 6 participants, so results may not apply widely. The drug may not improve symptoms or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The University of Tokyo Hospital
Tokyo, Japan